Exelixis traded at $17.62 this Tuesday January 31st, increasing $0.23 or 1.32 percent since the previous trading session. Looking back, over the last four weeks, Exelixis gained 8.10 percent. Over the last 12 months, its price fell by 4.34 percent. Looking ahead, we forecast Exelixis to be priced at 16.90 by the end of this quarter and at 15.29 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 4,090.00 -45.00 -1.09% 23.75%
Eisai 8,012.00 -97.00 -1.20% 39.61%
Acadia Pharmaceuticals 19.03 0.50 2.70% -20.18%
Agios Pharmaceuticals 29.48 0.29 0.99% -8.33%
Akebia Therapeutics 0.63 0.03 4.30% -68.81%
Amgen 252.40 0.81 0.32% 10.37%
AstraZeneca 10,592.00 -118.00 -1.10% 24.48%
Bayer 56.94 0.04 0.07% 5.13%
Bluebird Bio 6.35 0.24 3.93% -18.59%
BioMarin Pharmaceutical 115.35 0.65 0.57% 28.97%
Bristol-Myers Squibb 72.65 0.62 0.86% 11.44%
Cytokinetics 42.48 1.42 3.46% 26.54%
Esperion Therapeutics 6.36 -0.14 -2.15% 43.57%
Exelixis 17.62 0.23 1.32% -4.34%
Genmab 2,667.00 5.00 0.19% 18.80%
Glaxosmithkline 35.26 0.14 0.40% -21.97%
Immunogen 4.60 0.09 2.00% -20.28%
Incyte Corp 85.14 1.49 1.78% 13.23%
Ionis Pharmaceuticals 39.87 0.63 1.61% 26.53%
Eli Lilly 344.15 3.65 1.07% 38.61%
MacroGenics 5.77 0.15 2.67% -51.76%
Merck & Co 107.41 1.32 1.24% 31.12%
Moderna Inc 176.06 -4.81 -2.66% 1.92%
Mirati Therapeutics 53.41 1.60 3.09% -56.58%
Neurocrine Biosciences 110.93 2.64 2.44% 40.03%
Nektar Therapeutics 2.72 0.11 4.21% -75.41%
Novartis 82.65 -0.52 -0.63% 1.91%
Puma Biotechnology 4.30 0.03 0.70% 64.75%
Pfizer 44.16 0.61 1.40% -16.79%
Ultragenyx Pharmaceutical 45.33 2.35 5.47% -37.08%
Seattle Genetics 139.48 -0.50 -0.36% 1.26%
Sanofi 49.14 0.57 1.17% -4.82%
Xencor 32.92 1.22 3.85% -1.73%

Indexes Price Day Year
USND 11585 190.74 1.67% -19.25%
US2000 1932 46.22 2.45% -5.79%
US400 2653 61.95 2.39% -0.37%

Exelixis
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.